Positron Emission Tomography/Magnetic Resonance Imaging in Patients

Case Comprehensive Cancer Center (Case CCC)

Status

Terminated

Conditions

Malignant Neoplasm

Melanoma

Unspecified Adult Solid Tumor, Protocol Specific

Colon Cancer

Lung Cancer

Lymphoma

Head and Neck Cancer

Unspecified Childhood Solid Tumor, Protocol Specific

Treatments

Device: magnetic resonance imaging with positron emission tomography scanning

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT01557881

CASE15Z11

NCI-2012-00169 (Registry Identifier)

Details and patient eligibility

About

This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging (MRI) in patients undergoing PET/computed tomography (CT). Diagnostic procedures, such as PET/MRI, may help doctors diagnose cancer or help doctors predict a patient's response to treatment

Full description

PRIMARY OBJECTIVES:

I. To acquire PET/MRI scans of 100 patients which will be compared with PET/CT scans of the same subjects. The PET/CT scans will be used to provide the gold standard for evaluating the image quality and quantitative performance of the PET/MRI scans. After comparison and evaluation of the imaging capabilities and performance of the sequential PET/MRI imaging system for these 100 subjects, a second cohort of hundred consecutive subjects may be necessary and again comparisons made to the current standard of PET imaging, PET/CT. This validation of the attenuation correction methods and quantitative accuracy of the PET/MRI device compared to PET/CT will be a continuous iterative process that will result in optimized performance of the PET/MRI and will be a key step in its becoming available to other clinical research projects both within the Seidman Cancer Center as well as in other institutions.

OUTLINE:

After undergoing standard PET/CT, patients undergo PET/MRI.

Enrollment

98 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Only patients who are referred by their physician to have a clinical PET/CT will be eligible to participate in the study
we propose to obtain a second PET/MRI on 100 patients after their clinical PET/CT imaging that spans several disease categories and includes the following cancers: lung, colon, melanoma, head/neck and lymphoma
In addition to oncology patients, we anticipate imaging a subset of non-cancer patients who will also be imaged subsequent to their clinical PET/CT who will be referrals from neurology and cardiology
All subjects will be at least 18 years old, or if under 18, parents or guardians must give consent
Subjects must be stable and have experienced no adverse events from previous clinical PET/CT examination

Exclusion criteria

Subjects who do not meet the above inclusion criteria
Subjects unwilling or unable to sign the informed consent form
Subjects who are cognitively impaired and thus unable to give informed consent
Subjects unable to undergo MRI scanning due to exclusion via University Hospital Case Medical Center (UHCMC) MRI restrictions (e.g. implanted metallic or electronic devices, hip or other joint replacements, history of kidney disease, unacceptable creatinine or glomerular filtration rate [GFR], etc)
Patients who are pregnant